Comphya key facts
as of Oct 2026- Developer of a novel implantable device designed to treat erectile dysfunction.
- Comphya is valued at approximately $80.8M as of Oct 2026 (last reported valuation).
- It has raised $16.8M.
- Notable investors include Venture Kick, Ecole Polytechnique Federale de Lausanne, Verve Ventures, Zürcher Kantonalbank, Venture (Switzerland) — 11 tracked in total.
- Status: Privately Held (backing).
Comphya's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Comphya: the Monday email on marks, rounds and moves
Comphya funding rounds
No funding rounds for Comphya are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Comphya
11+Comphya valuation
Comphya's last reported valuation was $80.8 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
Comphya investors
11 investors are on record for Comphya, including Venture Kick, Ecole Polytechnique Federale de Lausanne, Verve Ventures and Zürcher Kantonalbank.
About Comphya
Developer of a novel implantable device designed to treat erectile dysfunction. The company's device provides self-controlled stimulation via a wireless remote control to the cavernous nerve to restore natural function, enabling patients to have a safe and effective alternative and improve their quality of life.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Employees
- 10
- Website
- comphya.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.